Reply to Giuseppe Di Lorenzo's Letter to the Editor re: Borje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel Sinescu. Renal Cell Cacinoma Guideline. Eur Urol 2007;51:1502-10.

摘要

The comments by Dr. Di Lorenzo about our review are much appreciated. His comments highlight the development and progression of the targeted therapies. In his letter to the editor, Dr. Lorenzo supplements our guidelines article in the section on systemic therapy. That portion reviewed level 1 data based on randomized phase 3 studies at that time. We furthermore summarized that the exact place of the new drugs is still open for discussion. Currently, no available data show that these new agents will cure the patient, but rather they seem to stabilize metastatic renal cell carcinoma for a prolonged period. This has to be understood within the toxicity profile of the drugs and the quality of life for the patients.